Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab versus placebo in hereditary periodic fever syndromes
NL-OMON44251Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab in TNF receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS) and Familial Mediterranean fever (FMF) (4 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Oct 2014; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
TNF receptor-associated periodic syndrome (TRAPS)hyperimmunoglobulin D syndrome (HIDS)Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NL-OMON44251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44251.